



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/612,497	07/01/2003	Douglas Charles Hanson	ABX-PF1 DIV1	3552

7590 07/06/2005

James F. Haley, Jr.  
FISH & NEAVE  
1251 Avenue of the Americas - 50th Floor  
New York, NY 10020

EXAMINER
----------

OUSPENSKI, ILIA I

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 07/06/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Notice of Allowability**

Application No.

10/612,497

Examiner

ILIA OUSPENSKI

Applicant(s)

HANSON ET AL.

Art Unit

1644

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 4/7/2005, 4/21/2005, 6/17/2005, 6/24/2005.
2. ☒ The allowed claim(s) is/are 116-124, 126-135, 137, 148-169, 171-190, 193-206, 209-222 and 225-235, renumbered 1-101.
3. ☒ The drawings filed on 01 July 2003 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some\* c) ☐ None of the:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.  
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached  
1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.  
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |   |   |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892)  | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)                                 |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413),<br>Paper No./Mail Date <u>6/16/05</u> . |
| 3. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),<br>Paper No./Mail Date <u>4/7/05, 4/21/05</u> . | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment   |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material  | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance                        |
|   | 9. <input type="checkbox"/> Other _____.  |

### DETAILED ACTION

1. Applicant's amendments, filed 04/21/2005, 06/17/2005, and 06/24/2005 are acknowledged.

Claims 1 – 115, 125, 136, 138 – 147, 170, 191, 192, 207, 208, 223, and 224 have been cancelled.

Claims 177 – 235 have been added.

Claims 116, 122, 124, 127, 128 – 133, 135, 137, 148, 149, 154, 156 – 158, 163 – 169, 171, 172, 174, and 176 have been amended.

*Claims 116 – 124, 126 – 135, 137, 148 – 169, 171 – 190, 193 – 206, 209 – 222, and 225 – 235 are pending.*

2. A Terminal Disclaimer filed on 04/21/2005 has obviated a previous double patenting rejection of record set forth in previous Office Action mailed 03/15/2005. The Terminal Disclaimer has been accepted on 04/28/2005.

3. Applicant's IDS, filed 04/07/2005 and 4/21/2005, are acknowledged, and have been considered.

4. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

***Examiner's Amendment***

In the Specification:

5. In the TITLE: The Title has been replaced with  
-- METHODS FOR EXPRESSING AND RECOVERING HUMAN  
MONOCLONAL ANTIBODIES TO CTLA-4 --

***Reasons for Allowance***

6. The following is an Examiner's Statement of Reasons for Allowance:

Applicant's amendments, filed 04/21/2005, 06/17/2005, and 06/24/2005, and the Terminal Disclaimer filed on 04/21/2005 have obviated the previous rejection of record, mailed 03/15/2005.

***Claims 116 – 124, 126 – 135, 137, 148 – 169, 171 – 190, 193 – 206, 209 – 222, and 225 – 235 are pending and allowed.***

The prior art does not teach or suggest the claimed methods for expressing and recovering human monoclonal antibodies to CTLA-4 with the claimed characteristics.

7. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1644

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA OUSPENSKI whose telephone number is 571-272-2920. The examiner can normally be reached on Monday-Friday 9 - 5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ILIA OUSPENSKI

Patent Examiner

Art Unit 1644

June 28, 2005

  
PHILLIP GAMBEL, PH.D  
PRIMARY EXAMINER  
Tech Center 1600  
6/30/05